TABLE 4

Effect of Repeated SB742457 Administration on ¹¹C-GSK215083 Uptake into Putamen, Caudate, and Frontal Cortex at 3 Dose Levels

	FRTM BP					% occupancy
Subject no.	Baseline	Day 7	Day 14	Day 21	Day 28	Day 7	Day 14	Day 21	Day 28	Mean occupancy
Putamen (5HT6)
Subject 11	1.085	No scan	∼	0.346	∼	No scan	∼	68	∼	68
Subject 12	0.909	0.324	∼	∼	0.297	64	∼	∼	67	66
Subject 13	1.001	∼	0.283	0.300	∼	∼	72	70	∼	71
Subject 14	1.359	∼	0.300	∼	0.328	∼	78	∼	76	77
										70
Subject 15	0.994	0.307	0.397	∼	∼	69	60	∼	∼	65
Subject 16	1.042	0.295	0.312	∼	∼	72	70	∼	∼	71
										68
Subject 17	0.890	0.350	0.411	∼	∼	61	54	∼	∼	58
Subject 18	1.052	0.379	0.328	∼	∼	64	69	∼	∼	67
										62
Caudate (5HT6)
Subject 11	0.510	No scan	∼	0.037	∼	No scan	∼	93	∼	93
Subject 12	0.912	0.067	∼	∼	0.178	93	∼	∼	81	87
Subject 13	1.092	∼	0.051	0.173	∼	∼	95	84	∼	90
Subject 14	1.044	∼	0.010	∼	0.121^*	∼	99	∼	88^*	99
										92
Subject 15	0.754	Poor fit	0.336	∼	∼	Poor fit	55	∼	∼	55
Subject 16	0.697	−0.052	0.004	∼	∼	108	99	∼	∼	104
										79
Subject 17	0.944	0.051	0.009	∼	∼	95	99	∼	∼	97
Subject 18	1.746	−0.061181	−0.027	∼	∼	104	102	∼	∼	103
										100
Frontal cortex (5HT2A)
Subject 11	0.272	No scan	∼	0.191	∼	No scan	∼	30	∼	30
Subject 12	0.228	0.087	∼	∼	0.108	62	∼	∼	53	58
Subject 13	0.238	∼	0.048	0.080	∼	∼	80	67	∼	74
Subject 14	0.257	∼	0.096	∼	0.072	∼	63	∼	72	68
										57
Subject 15	0.373	0.277	0.196	∼	∼	26	48	∼	∼	37
Subject 16	0.273	0.162	0.211	∼	∼	41	23	∼	∼	32
										35
Subject 17	0.280	0.190	0.213	∼	∼	32	24	∼	∼	28
Subject 18	0.269	0.223	0.215	∼	∼	17	20			19
										23

↵* SRTM value (FRTM value = 0.48808).